Epizyme (EPZM) Offers Prelim. Data from Tazemetostat Phase 2 in NHL; Favorable Safety Profile Noted
Tweet Send to a Friend
Epizyme, Inc. (Nasdaq: EPZM) reported preliminary data from its ongoing, global Phase 2 clinical trial of orally administered tazemetostat, a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
